Exeltis USA announced the commercial launch of Slynd (drospirenone), which is indicated for use by females of reproductive potential to prevent pregnancy.
Slynd is a progestin-only contraceptive that lowers the risk of becoming pregnant primarily by suppressing ovulation. It contains the synthetic progestin drospirenone in a 4mg dosage strength that is given in a 24/4 dose regimen.
Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity. Due to the risk of hyperkalemia, serum potassium levels should be checked prior to starting treatment and during the first treatment cycle in females receiving daily, long-term treatment for chronic conditions of diseases with medications that may increase serum potassium concentrations. In clinical trials, most females with hyperkalemia had mild potassium elevations and/or isolated increases that returned to normal while still on study medication.
Slynd is contraindicated in patients with: renal impairment, adrenal insufficiency, presence or history of cervical cancer or progestin sensitive cancers, liver tumors (benign or malignant), hepatic impairment, and undiagnosed abnormal uterine bleeding.
Salustiano Perez, President of Exeltis USA, Inc. noted that “Slynd is a [progestin-only pill] that may fit the lifestyle of more patient types, especially breastfeeding mothers seeking a safe and effective oral contraceptive without the risks of estrogen and some of the dosing challenges.”
Slynd is supplied in blister cards containing 24 white round active film-coated tablets, each containing 4mg drospirenone, and 4 green round inert film-coated tablets.
For more information visit exeltisusa.com.